New Zealand markets close in 2 hours 38 minutes

Shanghai Junshi Biosciences Co., Ltd. (1877.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
11.880+0.100 (+0.85%)
As of 10:06AM HKT. Market open.
Full screen
Previous close11.780
Open11.980
Bid11.820 x 0
Ask11.880 x 0
Day's range11.720 - 11.980
52-week range9.170 - 25.800
Volume4,800
Avg. volume1,189,632
Market cap27.066B
Beta (5Y monthly)0.33
PE ratio (TTM)N/A
EPS (TTM)-2.260
Earnings date28 Aug 2024 - 02 Sept 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est39.11
  • GlobeNewswire

    Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Small Cell Lung Cancer

    SHANGHAI, June 18, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the National Medical Products Administration (NMPA) has approved the supplemental new drug application (sNDA) for toripalimab (product code: JS001) in combination with etoposide plus platinum for the first-line treatment

  • GlobeNewswire

    Junshi Biosciences Announces Phase 3 Study of Toripalimab Combined with Bevacizumab for the First-line Treatment of Advanced Hepatocellular Carcinoma Meets Primary Endpoint

    SHANGHAI, June 11, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the primary endpoints of progression-free survival (“PFS,” based on independent radiographic review) and overall survival (“OS”) of a multi-center, randomized, open-label, active-controlled phase III clinical study (th

  • GlobeNewswire

    Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab

    SHANGHAI, China, April 24, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the Drug Office, Department of Health, the Government of the Hong Kong Special Administrative Region (“DO”) has recently accepted the New Drug Application (“NDA”) for toripalimab in combination with cisplatin a